| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 561,750 | $780,832 | $1.39 | 02 Feb 2026 | Direct |
| Akebia Therapeutics, Inc. | Chief Commercial Officer | Stock Option (Right to buy) | 320,000 | 30 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | 02 Feb 2026 | 2 | -$117,912 | 4 | Chief Commercial Officer | 04 Feb 2026, 16:13 |
| AKBA | Akebia Therapeutics, Inc. | 30 Jan 2026 | 2 | $0 | 4 | Chief Commercial Officer | 03 Feb 2026, 16:42 |
| AKBA | Akebia Therapeutics, Inc. | 31 Jan 2025 | 3 | -$116,804 | 4 | Chief Commercial Officer | 04 Feb 2025, 17:51 |
| AKBA | Akebia Therapeutics, Inc. | 31 Jan 2024 | 2 | $0 | 4 | Chief Commercial Officer | 02 Feb 2024, 16:11 |
| AKBA | Akebia Therapeutics, Inc. | 08 Jan 2024 | 0 | $0 | 3 | Chief Commercial Officer | 18 Jan 2024, 17:21 |